Xalkori crizotinib: Phase II data

Top-line data from the open-label, East Asian Phase II OO-1201 trial in 127 patients with ROS1-positive NSCLC showed that twice-daily 250 mg oral Xalkori led to an ORR of 69.3%, including 14 complete responses and 74 partial responses. Median PFS was 13.4 months and median time to response was 1.9 months. Additionally, 6- and 12-month OS rates were 92% and 84.4%, respectively. Data were presented at the American Society of Clinical Oncology meeting in Chicago. ...